Saturday 17 October 2026
Export PRFX’s income statement to Excel — free account
PainReform Ltd.
PRFX Healthcare Drug Manufacturers Specialty & Generic
PainReform Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $17,000.00.
0.81
0.04
−4.71%
Follow PRFX
PainReform Ltd. (PRFX) P/E ratio
PainReform Ltd. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| IMCC IM Cannabis Corp. compare | n/m |
| RDHL Redhill Biopharma Ltd. compare | n/m |
| BTAIQ BioXcel Therapeutics, Inc. compare | n/m |
| SNOA Sonoma Pharmaceuticals, Inc. compare | n/m |
| PRFX PainReform Ltd. | n/m |
| NEPTF Neptune Wellness Solutions Inc. compare | n/m |
| YCBD cbdMD, Inc. compare | 41.2× |
| GELS Gelteq Limited compare | — |
| AKAN Akanda Corp. compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)